Tuesday, November 17, 2020

Kinnate Biopharma Files For $100M IPO

San Diego-based Kinnate Biopharma has filed for an IPO, saying in a filing that it is looking to raise up to $100M. The company has filed to trade on the Nasdaq Global Select Market under the symbol KNTE. The IPO is being underwritten by Goldman Sachs & Co. LLC, SVB Leerink, and Piper Sandler. The firm is backed by Foresite Capital, OrbiMed, RA Capital Management, Nextech, and Vida Ventures. Kinnate Biopharma is focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers.